265 related articles for article (PubMed ID: 31766266)
21. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
22. Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer.
Han YL; Chen L; Qin R; Wang GQ; Lin XH; Dai GH
World J Gastroenterol; 2019 Apr; 25(15):1828-1839. PubMed ID: 31057297
[TBL] [Abstract][Full Text] [Related]
23. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
Chen Q; Ge X; Zhang Y; Xia H; Yuan D; Tang Q; Chen L; Pang X; Leng W; Bi F
Oncol Rep; 2014 Apr; 31(4):1863-70. PubMed ID: 24481716
[TBL] [Abstract][Full Text] [Related]
24. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
25. DEK modulates both expression and alternative splicing of cancer‑related genes.
Liu B; Sun Y; Zhang Y; Xing Y; Suo J
Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35475534
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.
Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH
Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811
[TBL] [Abstract][Full Text] [Related]
27. DEK protein level is a biomarker of CD138positive normal and malignant plasma cells.
Çalışkaner ZO; Çakar T; Özçelik E; Özdilek A; Kim AS; Doğan Ö; Bosompem A; Grosveld G; Saka B; Kandilci A
PLoS One; 2017; 12(5):e0178025. PubMed ID: 28558048
[TBL] [Abstract][Full Text] [Related]
28. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
29. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
30. Serum ENA78/CXCL5, SDF-1/CXCL12, and their combinations as potential biomarkers for prediction of the presence and distant metastasis of primary gastric cancer.
Lim JB; Chung HW
Cytokine; 2015 May; 73(1):16-22. PubMed ID: 25689618
[TBL] [Abstract][Full Text] [Related]
31. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
32. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
33. Potential diagnostic and prognostic value of plasma long noncoding RNA LINC00086 and miR-214 expression in gastric cancer.
Ji B; Huang Y; Gu T; Zhang L; Li G; Zhang C
Cancer Biomark; 2019; 24(2):249-255. PubMed ID: 30689553
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis.
Zheng R; Liang J; Lu J; Li S; Zhang G; Wang X; Liu M; Wang W; Chu H; Tao G; Zhao Q; Wang M; Du M; Qiang F; Zhang Z
Gastric Cancer; 2019 Jul; 22(4):731-741. PubMed ID: 30603909
[TBL] [Abstract][Full Text] [Related]
35. CircRNA
Li R; Tian X; Jiang J; Qian H; Shen H; Xu W
Biomarkers; 2023 Dec; 28(5):448-457. PubMed ID: 37128800
[TBL] [Abstract][Full Text] [Related]
36. KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer.
Jia S; Qu T; Wang X; Feng M; Yang Y; Feng X; Ma R; Li W; Hu Y; Feng Y; Ji K; Li Z; Jiang W; Ji J
PLoS One; 2017; 12(4):e0175058. PubMed ID: 28422983
[TBL] [Abstract][Full Text] [Related]
37. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
38. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
[TBL] [Abstract][Full Text] [Related]
39. Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract.
Kuo YJ; Lewis JS; Truong T; Yeh YC; Chernock RD; Zhai C; Chen YA; Hongo T; Lee CK; Shi Q; Velez Torres JM; Geromes AB; Chu YH; Hsieh MS; Yamamoto H; Weinreb I; Hang JF
Mod Pathol; 2022 Nov; 35(11):1587-1595. PubMed ID: 35701667
[TBL] [Abstract][Full Text] [Related]
40. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
